サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1192997

糖尿病治療薬市場：製品別（注射剤、経口糖尿病治療薬）：世界の機会分析および産業予測、2020-2030年

Diabetes Therapeutics Market By Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030
出版日: | 発行: Allied Market Research | ページ情報: 英文 160 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
糖尿病治療薬市場：製品別（注射剤、経口糖尿病治療薬）：世界の機会分析および産業予測、2020-2030年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 160 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病治療薬の世界市場は、2020年には1,180億6,330万米ドルとなり、2021年から2030年にかけてCAGR10.4%で成長し、2030年には3,179億1,500万米ドルに達すると予測されます。

糖尿病は、血糖値に異常がある慢性代謝疾患です。糖尿病治療薬は、糖尿病患者が体内の血糖値を維持するために使用する薬剤です。

世界の糖尿病治療薬市場は、糖尿病の有病率の上昇、高い肥満、座りがちなライフスタイル、その他の慢性疾患により、近い将来に大きな成長を記録すると予想されています。例えば、国際糖尿病連合（IDF）、糖尿病アトラスによると、2021年には、約5億3700万人の成人（20～79歳）が糖尿病と共存しています。さらに、老年人口の増加が糖尿病治療薬市場の成長につながりました。しかし、抗糖尿病薬による副作用が、予測期間中の市場成長を阻害しています。逆に、糖尿病分野における研究開発活動への資金提供の増加は、市場参加者に有益な機会を提供すると期待されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 糖尿病治療薬市場：製品別

  • 概要
    • 市場規模および予測
  • 注射剤
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 経口糖尿病治療薬
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第5章 糖尿病治療薬市場：地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主要動向と機会
    • 北米市場規模・予測：製品別
    • 北米の市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州市場規模・予測：製品別
    • 欧州市場規模・予測：国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：製品別
    • アジア太平洋地域の市場規模・予測：国別
      • 中国
      • 日本
      • インド
      • オーストラリア
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：製品別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ
      • その他のLAMEAの地域

第6章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第7章 企業プロファイル

  • ASTRAZENECA PLC
  • BOEHRINGER INGELHEIM GMBH
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE PLC
  • NOVARTIS AG
  • NOVO NORDISK
  • SANOFI S.A.
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • johnson and johnson md&d
  • MERCK and CO., INC.
図表

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 2. DIABETES THERAPEUTICS MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)
  • TABLE 3. DIABETES THERAPEUTICS MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 4. DIABETES THERAPEUTICS MARKET REVENUE, FOR ORAL ANTIDIABETIC DRUGS, BY REGION , 2020-2030,($MILLION)
  • TABLE 5. DIABETES THERAPEUTICS MARKET ORAL ANTIDIABETIC DRUGS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2020-2030,($MILLION)
  • TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 9. U.S. DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 10. CANADA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 11. MEXICO DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 12. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 13. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 14. GERMANY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 15. FRANCE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 16. UNITED KINGDOM DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 17. ITALY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 18. SPAIN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 19. REST OF EUROPE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 20. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 21. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 22. CHINA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 23. JAPAN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 24. INDIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 25. AUSTRALIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 26. REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 27. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 28. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 29. BRAZIL DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 30. SAUDI ARABIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 31. SOUTH AFRICA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 32. REST OF LAMEA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 33.ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 34.ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 35.ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 36.ASTRAZENECA PLC: NET SALES,
  • TABLE 37.ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 38.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 39.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
  • TABLE 40.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 41.BOEHRINGER INGELHEIM GMBH: NET SALES,
  • TABLE 42.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
  • TABLE 43.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 44.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 45.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 46.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 47.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 48.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 49.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 50.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 51.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 52.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 53.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 54.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 55.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 56.NOVARTIS AG: NET SALES,
  • TABLE 57.NOVARTIS AG: KEY STRATERGIES
  • TABLE 58.NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 59.NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 60.NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 61.NOVO NORDISK: NET SALES,
  • TABLE 62.NOVO NORDISK: KEY STRATERGIES
  • TABLE 63.SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 64.SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 65.SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 66.SANOFI S.A.: NET SALES,
  • TABLE 67.SANOFI S.A.: KEY STRATERGIES
  • TABLE 68.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 69.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 70.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 71.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
  • TABLE 72.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
  • TABLE 73.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
  • TABLE 74.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
  • TABLE 75.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
  • TABLE 76.JOHNSON AND JOHNSON MD&D: NET SALES,
  • TABLE 77.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
  • TABLE 78.MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 79.MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 80.MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 81.MERCK AND CO., INC.: NET SALES,
  • TABLE 82.MERCK AND CO., INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.DIABETES THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2.DIABETES THERAPEUTICS MARKET,2020-2030
  • FIGURE 3.DIABETES THERAPEUTICS MARKET,2020-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.DIABETES THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.DIABETES THERAPEUTICS MARKET,BY PRODUCT,2020(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INJECTABLES DIABETES THERAPEUTICS MARKET,2020-2030(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ORAL ANTIDIABETIC DRUGS DIABETES THERAPEUTICS MARKET,2020-2030(%)
  • FIGURE 15.DIABETES THERAPEUTICS MARKET BY REGION,2020
  • FIGURE 16.U.S. DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 17.CANADA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 18.MEXICO DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 19.GERMANY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 20.FRANCE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 21.UNITED KINGDOM DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 22.ITALY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 23.SPAIN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 24.REST OF EUROPE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 25.CHINA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 26.JAPAN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 27.INDIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 28.AUSTRALIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 29.REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 30.BRAZIL DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 31.SAUDI ARABIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 32.SOUTH AFRICA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 33.REST OF LAMEA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 34. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 37.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 38.COMPETITIVE DASHBOARD
  • FIGURE 39.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 40.ASTRAZENECA PLC.: NET SALES ,($MILLION)
  • FIGURE 41.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)
  • FIGURE 42.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 43.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 44.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 45.NOVO NORDISK.: NET SALES ,($MILLION)
  • FIGURE 46.SANOFI S.A..: NET SALES ,($MILLION)
  • FIGURE 47.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
  • FIGURE 48.JOHNSON AND JOHNSON MD&D.: NET SALES ,($MILLION)
  • FIGURE 49.MERCK AND CO., INC..: NET SALES ,($MILLION)
目次
Product Code: A03202

The global diabetes therapeutics market was valued at $118,063.3 million in 2020, and is projected to reach $317,915 million by 2030, registering a CAGR of 10.4% from 2021 to 2030. Diabetes is a chronic metabolic disorder in which there are abnormalities in blood glucose levels. Diabetes therapeutics are drugs used by diabetic patients to conserve the blood glucose levels in the body.

The global diabetes therapeutics market is expected to register substantial growth in the near future, owing to rise in prevalence of diabetes, high obesity, sedentary lifestyles, and other chronic conditions. For instance, according to International Diabetes Federation (IDF),Diabetes Atlas, in 2021, approximately 537 million adults (20-79 years of age) were living with diabetes.  Furthermore, rise in geriatric population led to an increase in growth of diabetes therapeutics market. However, side effects caused by anti-diabetes medication hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities in diabetes sector is expected to offer remunerative opportunities for market players.

The diabetes therapeutics market is segmented into product and region. By product, the market is categorized into injectables and oral-antidiabetic drugs (OAD). By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag ,Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global diabetes therapeutics market size along with the current trends and future estimations to elucidate the future investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of the region helps to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global diabetes therapeutics market growth.

Key Market Segments

By Product

  • Injectables
  • Oral antidiabetic Drugs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • ASTRAZENECA PLC
    • BOEHRINGER INGELHEIM GMBH
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE PLC
    • NOVARTIS AG
    • NOVO NORDISK
    • SANOFI S.A.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • johnson and johnson md&d
    • MERCK and CO., INC.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETES THERAPEUTICS MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Injectables
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Oral antidiabetic Drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: DIABETES THERAPEUTICS MARKET, BY REGION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 North America
    • 5.2.1 Key trends and opportunities
    • 5.2.2 North America Market size and forecast, by Product
    • 5.2.3 North America Market size and forecast, by country
      • 5.2.3.1 U.S.
      • 5.2.3.1.1 Market size and forecast, by Product
      • 5.2.3.2 Canada
      • 5.2.3.2.1 Market size and forecast, by Product
      • 5.2.3.3 Mexico
      • 5.2.3.3.1 Market size and forecast, by Product
  • 5.3 Europe
    • 5.3.1 Key trends and opportunities
    • 5.3.2 Europe Market size and forecast, by Product
    • 5.3.3 Europe Market size and forecast, by country
      • 5.3.3.1 Germany
      • 5.3.3.1.1 Market size and forecast, by Product
      • 5.3.3.2 France
      • 5.3.3.2.1 Market size and forecast, by Product
      • 5.3.3.3 United Kingdom
      • 5.3.3.3.1 Market size and forecast, by Product
      • 5.3.3.4 Italy
      • 5.3.3.4.1 Market size and forecast, by Product
      • 5.3.3.5 Spain
      • 5.3.3.5.1 Market size and forecast, by Product
      • 5.3.3.6 Rest of Europe
      • 5.3.3.6.1 Market size and forecast, by Product
  • 5.4 Asia-Pacific
    • 5.4.1 Key trends and opportunities
    • 5.4.2 Asia-Pacific Market size and forecast, by Product
    • 5.4.3 Asia-Pacific Market size and forecast, by country
      • 5.4.3.1 China
      • 5.4.3.1.1 Market size and forecast, by Product
      • 5.4.3.2 Japan
      • 5.4.3.2.1 Market size and forecast, by Product
      • 5.4.3.3 India
      • 5.4.3.3.1 Market size and forecast, by Product
      • 5.4.3.4 Australia
      • 5.4.3.4.1 Market size and forecast, by Product
      • 5.4.3.5 Rest Of Asia Pacific
      • 5.4.3.5.1 Market size and forecast, by Product
  • 5.5 LAMEA
    • 5.5.1 Key trends and opportunities
    • 5.5.2 LAMEA Market size and forecast, by Product
    • 5.5.3 LAMEA Market size and forecast, by country
      • 5.5.3.1 Brazil
      • 5.5.3.1.1 Market size and forecast, by Product
      • 5.5.3.2 Saudi Arabia
      • 5.5.3.2.1 Market size and forecast, by Product
      • 5.5.3.3 South Africa
      • 5.5.3.3.1 Market size and forecast, by Product
      • 5.5.3.4 Rest of LAMEA
      • 5.5.3.4.1 Market size and forecast, by Product

CHAPTER 6: COMPANY LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product Mapping of Top 10 Player
  • 6.4. Competitive Dashboard
  • 6.5. Competitive Heatmap
  • 6.6. Key developments

CHAPTER 7: COMPANY PROFILES

  • 7.1 ASTRAZENECA PLC
    • 7.1.1 Company overview
    • 7.1.2 Company snapshot
    • 7.1.3 Operating business segments
    • 7.1.4 Product portfolio
    • 7.1.5 Business performance
    • 7.1.6 Key strategic moves and developments
  • 7.2 BOEHRINGER INGELHEIM GMBH
    • 7.2.1 Company overview
    • 7.2.2 Company snapshot
    • 7.2.3 Operating business segments
    • 7.2.4 Product portfolio
    • 7.2.5 Business performance
    • 7.2.6 Key strategic moves and developments
  • 7.3 ELI LILLY AND COMPANY
    • 7.3.1 Company overview
    • 7.3.2 Company snapshot
    • 7.3.3 Operating business segments
    • 7.3.4 Product portfolio
    • 7.3.5 Business performance
    • 7.3.6 Key strategic moves and developments
  • 7.4 GLAXOSMITHKLINE PLC
    • 7.4.1 Company overview
    • 7.4.2 Company snapshot
    • 7.4.3 Operating business segments
    • 7.4.4 Product portfolio
    • 7.4.5 Business performance
    • 7.4.6 Key strategic moves and developments
  • 7.5 NOVARTIS AG
    • 7.5.1 Company overview
    • 7.5.2 Company snapshot
    • 7.5.3 Operating business segments
    • 7.5.4 Product portfolio
    • 7.5.5 Business performance
    • 7.5.6 Key strategic moves and developments
  • 7.6 NOVO NORDISK
    • 7.6.1 Company overview
    • 7.6.2 Company snapshot
    • 7.6.3 Operating business segments
    • 7.6.4 Product portfolio
    • 7.6.5 Business performance
    • 7.6.6 Key strategic moves and developments
  • 7.7 SANOFI S.A.
    • 7.7.1 Company overview
    • 7.7.2 Company snapshot
    • 7.7.3 Operating business segments
    • 7.7.4 Product portfolio
    • 7.7.5 Business performance
    • 7.7.6 Key strategic moves and developments
  • 7.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 7.8.1 Company overview
    • 7.8.2 Company snapshot
    • 7.8.3 Operating business segments
    • 7.8.4 Product portfolio
    • 7.8.5 Business performance
    • 7.8.6 Key strategic moves and developments
  • 7.9 johnson and johnson md&d
    • 7.9.1 Company overview
    • 7.9.2 Company snapshot
    • 7.9.3 Operating business segments
    • 7.9.4 Product portfolio
    • 7.9.5 Business performance
    • 7.9.6 Key strategic moves and developments
  • 7.10 MERCK and CO., INC.
    • 7.10.1 Company overview
    • 7.10.2 Company snapshot
    • 7.10.3 Operating business segments
    • 7.10.4 Product portfolio
    • 7.10.5 Business performance
    • 7.10.6 Key strategic moves and developments